Search Results
Your search for all items matches 30470 pages
Showing 101 - 150Dinutuximab Beta and Interleukin-2 After Haploidentical Stem Cell Transplantation in Patients With Relapsed Neuroblastoma
In a phase I/II trial reported in the Journal of Clinical Oncology, Flaadt et al found that treatment with the anti-GD2 antibody dinutuximab beta plus low-dose interleukin-2 (IL-2) following haploidentical stem cell transplantation (haplo-SCT) is feasible in patients with relapsed high-risk...
Neoadjuvant Plus Adjuvant vs Adjuvant Pembrolizumab in Advanced Melanoma
In the phase II SWOG Cancer Research Network S1801 trial reported in The New England Journal of Medicine, Sapna P. Patel, MD, and colleagues found that neoadjuvant plus adjuvant pembrolizumab significantly improved event-free survival vs adjuvant pembrolizumab alone in patients with stage IIIB to...
Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma: 5-Year Results of the ZUMA-1 Trial
As reported in the journal Blood by Sattva S. Neelapu, MD, and colleagues, 5-year outcomes from the the phase II ZUMA-1 trial showed that axicabtagene ciloleucel was associated with maintained response in one-third of patients with refractory large B-cell lymphoma. The estimated 5-year overall...
FDA Expands Early Breast Cancer Indication for Abemaciclib Plus Endocrine Therapy
On March 3, the U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio) plus endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer at high risk of...
First-Line Pembrolizumab in Older Patients With dMMR Metastatic Colorectal Cancer
In a retrospective cohort study reported in JAMA Network Open, Saberzadeh-Ardestani et al found that first-line pembrolizumab was associated with clinically significant prolongation of survival outcomes in mostly older patients with mismatch repair–deficient (dMMR) metastatic colorectal cancer....
2023 ASCO Genitourinary Cancers Symposium: Focus on Prostate Cancer
On this episode, we’re continuing our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We’ll hear from three researchers about their findings in prostate cancer trials reported at the meeting.
Access to Paid Sick Leave May Result in More Cancer Screenings
More individuals may undergo cancer screenings when employers are mandated to provide paid sick leave, according to a new study published by Callison et al in The New England Journal of Medicine. Researchers found that breast cancer screening rates increased up to 4% and colorectal cancer...
Hormone Therapy May Reduce Risk of Lung Cancer in Female Patients, Despite Former Misperceptions
Investigators have demonstrated that, despite some commonly held misperceptions, hormone therapy doesn’t increase patients’ risk of developing lung cancer—and it could help reduce the risk, according to a 16-year population-based study published by Wu et al in Menopause. The findings may help...
Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer
In the phase II CALYPSO study reported in the Journal of Clinical Oncology, Suárez et al found that the combination of the MET inhibitor savolitinib and the PD-L1 inhibitor durvalumab did not reach the confirmed response rate endpoint in patients with metastatic papillary renal cancer but showed...
Surgeon-Anesthesiologist Familiarity and Short-Term Outcomes in Complex Gastrointestinal Cancer Surgery
In a Canadian population–based retrospective cohort study reported in JAMA Surgery, Hallet et al found that increased familiarity among surgeon-anesthesiologist dyads—measured by annual number of procedures performed together—was associated with better short-term postoperative outcomes in complex...
Cancer Organizations Respond to Turkey and Syria Earthquakes
On February 6, 2023, a powerful 7.8-magnitude earthquake, followed by a second 7.5-magnitude quake, struck southeast Turkey and northwest Syria. To date, the quakes and several major aftershocks have killed nearly 52,000 citizens—more than 45,000 in Turkey and more than 6,700 in Syria—and injured...
Black Women at High Risk of Breast Cancer May Face Obstacles in Receiving Preventive Care
Black women at high risk of developing breast cancer may face a variety of obstacles keeping them from receiving preventive care that could increase their chances of survival if they did develop the disease, according to a new study published by Padamsee et al in PLOS One. The new findings provide...
Vitamin B5 May Help Improve Red Blood Cell Production in Patients With Myelodysplastic Syndromes
Researchers have discovered that vitamin B5 in combination with existing drugs may be the key to improving outcomes in patients with myelodysplastic syndromes (MDS) and ineffective red blood cell production, according to a novel study published by Mian et al in Science Translational Medicine....
Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Patients With Cancer
In an analysis reported in JACC: CardioOncology, Zhu et al found that in the United States, Black patients with cancer were at increased risk of all-cause mortality and cardiovascular (CVD) mortality compared with White patients, and that White patients were at increased risk of both outcomes...
Prognosis of HER2-Low vs HER2-Negative Breast Cancer
In an analysis of National Cancer Database data reported in JAMA Oncology, Peiffer et al found “minimal prognostic differences” between HER2-low vs HER2-negative breast cancer, with the findings not supporting classification of HER2-low disease as a distinct disease subtype. Study Details The...
Can Long Noncoding RNA Expression Help Predict Outcomes in Pediatric Patients With AML?
In a study reported in the Journal of Clinical Oncology, Farrar et al developed a long noncoding RNA (lncRNA) transcription scoring system that distinguished survival outcomes in pediatric patients with acute myeloid leukemia (AML). As stated by the investigators, “Risk classification in pediatric...
How Patient Navigation Programs Are Helping Drive Equitable Care for Patients With Cancer and Improve Outcomes
Although patient navigation is increasingly recognized as an important component in the delivery of patient-centered cancer care, the service is not universally available across all cancer programs in the United States, often because of the concerns of extra cost without tangible financial...
Vadim S. Koshkin, MD, and Tanya Jindal, BS, BA, on Urothelial Carcinoma: Biomarkers of Response to Enfortumab Vedotin-ejfv
Vadim S. Koshkin, MD, and Tanya Jindal, BS, BA, both of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discuss results from the retrospective UNITE study of biomarkers of response to the antibody-drug conjugate enfortumab vedotin-ejfv in patients with...
Updates From City of Hope on Renal Cell, Prostate, and Urothelial Cancers
Sumanta K. Pal, MD, introduces his City of Hope colleagues, Hedyeh Ebrahimi, MD, MPH, who discusses the prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma, and Daniela Castro, MSc, who discusses expanding eligibility criteria in kidney, prostate,...
American Cancer Society Data Show Colorectal Cancer Rates Are Rising in Younger Adults and Shifting to More Advanced Disease in People of All Ages
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall, and is the leading cause of death in ...
Association of Baseline and Subsequent Cardiovascular Health Metrics With Risk for Incident Cancers
In an analysis from the French GAZEL study reported in JACC: CardioOncology, Van Sloten et al found that better cardiovascular health scores at baseline and improvement in scores over 7 years were associated with a reduced risk of incident cancers. As stated by the investigators, “The commonality...
Addition of Pembrolizumab to Pemetrexed/Platinum in the First-Line Treatment of Metastatic Nonsquamous NSCLC: 5-Year Outcomes in the KEYNOTE-189 Study
As reported in the Journal of Clinical Oncology by Marina C. Garassino, MD, and colleagues, 5-year follow-up in the phase III KEYNOTE-189 trial has shown maintained progression-free and overall survival benefits with the addition of pembrolizumab to pemetrexed and platinum chemotherapy in the...
Combination Chemotherapy May Be Safe and Effective Alternative for the Treatment of Patients With Non–Muscle-Invasive Bladder Cancer Amid BCG Shortage
Researchers have found that a safe, inexpensive chemotherapy combination may be better tolerated and more effective at preventing high-grade recurrence in patients with non–muscle-invasive bladder cancer than the standard-of-care bacillus Calmette-Guérin (BCG), according to a novel study published...
Prediction Models for Kidney Failure in Long-Term Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Wu et al developed models for predicting kidney failure among 5-year survivors of childhood cancer. Study Details In the study, predictive models were developed using data from 25,483 survivors from the Childhood Cancer Survivor Study (CCSS)...
Survival in Patients With Brain Metastases: Limited or Stable Extracranial Disease
In a systematic review and meta-analysis reported in JAMA Network Open, Li et al found that patients with intracranial metastatic disease in the context of limited or stable extracranial disease (IMD-SE) secondary to any primary cancer had improved overall survival vs those with intracranial...
Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: New Phase II Data on Cabozantinib and Checkpoint Inhibitor Therapy
Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discusses interim results from the CaboPoint study, which evaluated cabozantinib as second-line treatment in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component. Disease in...
Daniel P. Petrylak, MD, on Urothelial Cancer: Phase II Trial Analysis of Sacituzumab Govitecan-hziy in Metastatic Disease
Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses a primary phase II analysis of the TROPHY-U-01 study, cohort 2, which evaluated sacituzumab govitecan-hziy in platinum-ineligible patients with metastatic urothelial cancer that progressed after prior checkpoint inhibitor therapy....
Hospital Surgical Volume May Impact Survival in Patients With Pancreatic Cancer Whose Minimally Invasive Surgery Is Converted to an Open Procedure
Patients with pancreatic ductal adenocarcinoma whose pancreatoduodenectomy is converted to an open (CTO) procedure from a minimally invasive procedure as a result of complications may fare better at institutions that perform more minimally invasive pancreatic cancer surgeries annually, according to ...
De-escalated Neoadjuvant T-DM1 With or Without ET vs Trastuzumab With ET in Hormone Receptor–Positive/HER2-Positive Early Breast Cancer
As reported in the Journal of Clinical Oncology by Nadia Harbeck, MD, PhD, and colleagues, 5-year follow-up from the phase II WSG-ADAPT-TP trial indicated that pathologic complete response (pCR) was associated with better outcomes irrespective of receipt of adjuvant chemotherapy among patients with ...
Immunotherapy Costs May Drive Increase in Medicare Spending for Outpatient End-of-Life Cancer Care
Researchers have discovered that recent increases in Medicare spending on outpatient end-of-life cancer care may have been driven almost entirely by costs associated with immunotherapy, which is given to fewer than one in five patients, according to a new study published by Mantz et al in the...
Combination Abatacept, Ruxolitinib, and/or Mechanical Ventilation May Decrease Mortality in Patients With Immune Checkpoint Inhibitor–Associated Cardiotoxicity
Although immune checkpoint inhibitors have substantially improved clinical outcomes in many cancer types, they have also been found to induce immune-related adverse events, including myocarditis, in about 1% of patients receiving the agents, which can lead to a mortality rate of up to 50%. Current...
Prevalence of High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Patients With BRCA1/2 Pathogenic Variants
In a Dutch study reported in the Journal of Clinical Oncology, Stroot et al identified the prevalence of high-grade serous carcinoma at risk-reducing salpingo-oophorectomy in asymptomatic BRCA1/2 pathogenic variant carriers. Study Details The study included asymptomatic BRCA1/2 pathogenic variant...
Darolutamide Plus ADT and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: Outcomes by Disease Volume and Risk Status in the ARASENS Trial
In an analysis from the phase III ARASENS trial reported in the Journal of Clinical Oncology, Maha Hussain, MD, FACP, FASCO, and colleagues found that the addition of darolutamide to androgen-deprivation therapy (ADT) and docetaxel significantly improved overall survival in subgroups of patients...
Michael B. Atkins, MD, on Renal Cell Carcinoma: Phase II Findings on Nivolumab and Ipilimumab
Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, discusses treatment-free survival outcomes from the HCRN GU16-260-Cohort A study of patients with previously untreated advanced clear cell renal cell carcinoma who received nivolumab and salvage nivolumab plus ipilimumab....
Matt D. Galsky, MD, on Bladder or Upper Urinary Tract Cancer: Extended Follow-up Results From CheckMate 274
Matt D. Galsky, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses results from CheckMate 274, which investigated nivolumab compared with placebo in patients with bladder or upper urinary tract cancer, following radical surgery to remove invasive disease....
Scott T. Tagawa, MD, on Prostate Cancer: Phase II Results on Ketoconazole, Hydrocortisone, and an Anti-PSMA Antibody
Scott T. Tagawa, MD, of Weill Cornell Medicine, NewYork-Presbyterian Hospital, discusses study results showing that, the anti-PSMA (prostate-specific membrane antigen) monoclonal antibody J591 with ketoconazole and hydrocortisone, when radiolabeled with lutetium-177, leads to improved 18-month...
Mediterranean Diet and Immune Checkpoint Blockade Outcomes in Advanced Melanoma
In the PRIMM study reported in JAMA Oncology, Bolte et al found that consumption of a Mediterranean diet was associated with a high probability of objective response and 12-month progression-free survival among patients receiving immune checkpoint blockade treatment for advanced melanoma. As stated ...
Association of Immune-Related Adverse Events With Overall Survival in Patients Receiving Atezolizumab-Containing Therapy for Metastatic Nonsquamous NSCLC
In a pooled analysis reported in JAMA Oncology, Mark A. Socinski, MD, and colleagues found that patients with nonsquamous non–small cell lung cancer (NSCLC) receiving atezolizumab who had grade 1 or 2 immune-related adverse events in clinical trials had improved overall survival vs those with no...
Remote Interventions to Improve Uptake of Cancer Genetic Risk Assessment in Patients With Ovarian Cancer or High-Risk Breast Cancer
In a study reported in the Journal of Clinical Oncology, Anita Y. Kinney, PhD, RN, and colleagues found that a phone-based tailored risk counseling and navigation intervention resulted in a higher proportion of patients with ovarian or high-risk breast cancers receiving cancer genetic risk...
Millions of U.S. Individuals May Have Missed Cancer Screenings During Second Year of COVID-19 Pandemic
Investigators have found that millions of individuals in the United States continued to miss critical cancer screening tests during the second year of the COVID-19 pandemic, according to a new study published by Star et al in the Journal of Clinical Oncology. Compared with 2019 levels, individuals...
New Study Demonstrates Inferior Vena Cava Filters May Be Safe and Effective Way to Prevent Venous Thromboembolism
Researchers have discovered that few adverse events may be associated with the use of inferior vena cava filters to help prevent deep vein thrombosis from developing into pulmonary embolisms, according to a new study jointly published by Johnson et al in the Journal of Vascular and Interventional...
Residual Nonretroperitoneal Disease After Chemotherapy for Nonseminomatous Germ Cell Tumors
In a single-institution study reported in the Journal of Clinical Oncology, King et al identified the prevalence of teratoma and active germ cell tumor in patients with residual nonretroperitoneal disease following chemotherapy for advanced nonseminomatous germ cell tumors. As stated by the...
Matt D. Galsky, MD, on Urothelial Carcinoma: New Study Results on Atezolizumab, Platinum, and Gemcitabine
Matt D. Galsky, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses final overall survival data from the phase III IMvigor130 study, which compared atezolizumab versus placebo, both of which were paired with platinum and gemcitabine in the first-line treatment...
Andrea Necchi, MD, on Bladder Cancer: Phase II Results With Pembrolizumab Monotherapy
Andrea Necchi, MD, of Italy’s Vita-Salute San Raffaele University and the IRCCS San Raffaele Hospital and Scientific Institute, discusses new data from the KEYNOTE-057 trial on a novel systemic therapy for papillary high-risk non–muscle-invasive bladder cancer. The findings suggest that patients...
2023 ASCO Genitourinary Cancers Symposium: Focus on RCC
On this episode, we’re sharing news from our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We’ll hear from two researchers about their findings in renal cell carcinoma (RCC).
Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
On January 19, 2023, the kinase inhibitor zanubrutinib was approved for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 Supporting Efficacy Data Approval was based on findings in the SEQUOIA trial (ClinicalTrials.gov identifier NCT03336333) in patients with...
Urologic Oncologist Hyung Kim, MD, Named Chair of Cedars-Sinai Department of Urology
Cedars-Sinai has appointed urologic oncologist, surgeon, and research investigator Hyung Kim, MD, as the inaugural Chair of the newly established Department of Urology. “Dr. Kim is an outstanding clinical and academic leader who will strategically steer our urology enterprise,” said Shlomo Melmed, ...
ASCO Updates ‘Living’ Guidelines on Stage IV NSCLC Based on DESTINY-Lung01, CodeBreaK100, Other Trials
ASCO has updated its living guidelines for therapy for stage IV non–small cell lung cancer (NSCLC) with and without driver alterations based on newly available evidence in the field.1,2 “Living guidelines are becoming more important as the field of oncology expands and developments occur more...
ASCO Endorses CAP Guideline to Better Define Who Benefits From Immune Checkpoint Inhibitor Therapy
ASCO has endorsed a new guideline from the College of American Pathologists (CAP) on the use of mismatch repair (MMR) and microsatellite instability (MSI) testing, which could help oncologists more accurately identify patients who may be suitable candidates for immune checkpoint inhibitor ...
Expert Point of View: Adam M. Brufsky, MD
Commenting on the study from Tata Memorial Centre for The ASCO Post, Adam M. Brufsky, MD, Professor of Medicine, Associate Chief of the Division of Hematology/Oncology and Co-Director of the Comprehensive Breast Cancer Center at the University of Pittsburgh School of Medicine, noted that the...
